Biomarkers in Alzheimer's and Parkinson's Diseases for IA

Investigate whether endogenous and exogenous risk factors, the presence of pathological amyloid aggregates and alpha-synuclein in the CSF, brain connectivity, and some clinical and biological indices such as vigilance, general motility, the sleep-wake cycle, genomic instability and possible DNA damage may correlate with (or predict) the clinical condition of mild cognitive impairment (MCI) and dementia in patients with Alzheimer's disease (AD) and Parkinson's disease (PD).

NCT Number	NCT07651085
Lead Sponsor	IRCCS San Raffaele Roma Collaborators: University of Roma La Sapienza, Azienda Ospedaliera di Padova, Azienda Ospedaliera OO.RR. S. Giovanni di Dio e Ruggi D'Aragona
Conditions	Parkinson Disease, Alzheimer Disease, Mild Cognitive Impairment, Dementia
Enrollment	65 participants
Start Date	2024-02-08
Primary Completion	2026-05-19 (estimated)
Study Completion	2027-07-20 (estimated)
Updated on ClinicalTrials.gov	2026-06-16